The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study


Autoři: Jung-Min Lee aff001;  Yong-Moon Park aff002;  Jae-Seung Yun aff001;  Yu-Bae Ahn aff001;  Kang-Moon Lee aff003;  Dae Bum Kim aff003;  Ji Min Lee aff003;  Kyungdo Han aff004;  Seung-Hyun Ko aff001
Působiště autorů: Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea aff001;  Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States of America aff002;  Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea aff003;  Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Korea aff004
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226351

Souhrn

We investigated the association between nonalcoholic fatty liver disease (NAFLD) and gastrointestinal tract cancer in the general population. Retrospective data on individuals aged ≥20 years who received healthcare checkups from January 1, 2009 to December 31, 2009 were analyzed using the National Health Insurance Database in Korea. NAFLD was defined based on the fatty liver index (FLI ≥60). The primary outcome was newly diagnosed esophageal, stomach, or colorectal cancer using ICD-10 codes during follow-up until 31 December 2017. Cox regression analysis was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Among 8,120,674 subjects, 936,159 adults (11.5%) were identified as having NAFLD. Their mean age was 46.7 ± 14.1 years, and 52.1% were male. During the follow-up period (7.2 years), 3,792 esophageal, 57,292 stomach and 68,769 colorectal cancer cases were identified. FLI ≥60 was significantly associated with the development of esophageal (HR 2.10, 95% CI 1.88–2.35), stomach (HR 1.18, 95% CI 1.14–1.22), and colon cancer (HR, 1.23, 95% CI 1.19–1.26) after multivariable adjustment. Compared to subjects without NAFLD, all-cause mortality in patients with esophageal (HR 1.46, 95% CI 1.28–1.67), stomach (HR 1.26, 95% CI 1.18–1.34), and colorectal cancer (HR 1.16, 95% CI 1.10–1.22) was significantly increased in subjects with NAFLD (FLI ≥60). NAFLD defined using FLI was a good predictive indicator for GI tract malignancy and all-cause mortality in the general population. Subjects with NAFLD are needed for active surveillance of esophageal, stomach, and colorectal cancers.

Klíčová slova:

Body mass index – Colorectal cancer – Death rates – Diabetes mellitus – Fatty liver – Obesity – Stomach – Genitourinary cancers


Zdroje

1. Goh LY, Leow AH, Goh KL. Observations on the epidemiology of gastrointestinal and liver cancers in the Asia-Pacific region. J Dig Dis. 2014;15(9):463–8. Epub 2014/06/05. doi: 10.1111/1751-2980.12164 24894597

2. Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut. 2011;60(6):745–6. Epub 2011/04/02. doi: 10.1136/gut.2011.239392 21454382

3. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology. 2016;63(3):776–86. Epub 2015/12/08. doi: 10.1002/hep.28376 26638128

4. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–90. Epub 2013/09/18. doi: 10.1038/nrgastro.2013.171 24042449

5. Corey KE, Kaplan LM. Obesity and liver disease: the epidemic of the twenty-first century. Clin Liver Dis. 2014;18(1):1–18. Epub 2013/11/28. doi: 10.1016/j.cld.2013.09.019 24274861

6. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22(9):1141–5. Epub 2005/08/20. doi: 10.1111/j.1464-5491.2005.01582.x 16108839

7. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19. Epub 2009/02/26. 19240815

8. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20(2):205–14. Epub 2016/04/12. doi: 10.1016/j.cld.2015.10.001 27063264

9. Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52(2):164–74. Epub 2016/09/18. doi: 10.1007/s00535-016-1264-3 27637587

10. Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, et al. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43(1):31–45. Epub 2019/02/23. doi: 10.4093/dmj.2019.0011 30793550

11. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40 Suppl 1:S11–6. Epub 2006/03/17. doi: 10.1097/01.mcg.0000168644.23697.31 16540761

12. Cornejo A, Salgado F, Caballero J, Vargas R, Simirgiotis M, Areche C. Secondary Metabolites in Ramalina terebrata Detected by UHPLC/ESI/MS/MS and Identification of Parietin as Tau Protein Inhibitor. Int J Mol Sci. 2016;17(8). Epub 2016/08/23. doi: 10.3390/ijms17081303 27548142

13. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama. 2015;313(22):2263–73. Epub 2015/06/10. doi: 10.1001/jama.2015.5370 26057287

14. Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270(1):41–9. Epub 2011/03/19. doi: 10.1111/j.1365-2796.2011.02377.x 21414047

15. Touzin NT, Bush KN, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2011;4(3):169–76. Epub 2011/06/23. doi: 10.1177/1756283X11402118 21694801

16. Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung SH, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther. 2017;45(2):345–53. Epub 2016/11/20. doi: 10.1111/apt.13866 27859470

17. Mikolasevic I, Orlic L, Stimac D, Hrstic I, Jakopcic I, Milic S. Non-alcoholic fatty liver disease and colorectal cancer. Postgrad Med J. 2017;93(1097):153–8. Epub 2016/11/18. doi: 10.1136/postgradmedj-2016-134383 27852946

18. Yang YJ, Bang CS, Shin SP, Baik GH. Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: Propensity score matching analysis. PLoS One. 2017;12(8):e0182014. Epub 2017/08/05. doi: 10.1371/journal.pone.0182014 28777831

19. Chen ZF, Dong XL, Huang QK, Hong WD, Wu WZ, Wu JS, et al. The combined effect of non-alcoholic fatty liver disease and metabolic syndrome on colorectal carcinoma mortality: a retrospective in Chinese females. World J Surg Oncol. 2018;16(1):163. Epub 2018/08/12. doi: 10.1186/s12957-018-1461-z 30097069

20. Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, Cheungpasitporn W, Treeprasertsuk S, Rerknimitr R, et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2017;17(1):149. Epub 2017/12/09. doi: 10.1186/s12876-017-0696-4 29216833

21. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. Epub 2006/11/04. doi: 10.1186/1471-230X-6-33 17081293

22. Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, et al. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine (Baltimore). 2015;94(40):e1682. Epub 2015/10/09. doi: 10.1097/md.0000000000001682 26448014

23. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201–4. Epub 2013/01/29. doi: 10.1016/j.cgh.2012.12.031 23353640

24. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. Epub 2016/04/12. doi: 10.1016/j.jhep.2015.11.004 27062661

25. Ze EY, Kim BJ, Jun DH, Kim JG, Kang H, Lee DY. The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. Dis Colon Rectum. 2018;61(1):36–42. Epub 2017/12/09. doi: 10.1097/DCR.0000000000000973 29219920

26. Jung CH, Chung JO, Han K, Ko SH, Ko KS, Park JY. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013). Cardiovasc Diabetol. 2017;16(1):1. Epub 2017/01/07. doi: 10.1186/s12933-016-0482-6 28057001

27. Kang SH, Choi EK, Han KD, Lee SR, Lim WH, Cha MJ, et al. Underweight is a risk factor for atrial fibrillation: A nationwide population-based study. Int J Cardiol. 2016;215:449–56. Epub 2016/05/02. doi: 10.1016/j.ijcard.2016.04.036 27131763

28. Ko SH, Han K, Lee YH, Noh J, Park CY, Kim DJ, et al. Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis. Diabetes Metab J. 2018;42(2):93–100. Epub 2018/04/21. doi: 10.4093/dmj.2018.42.2.93 29676539

29. Lee YH, Han K, Ko SH, Ko KS, Lee KU. Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance Service. Diabetes Metab J. 2016;40(1):79–82. Epub 2016/02/26. doi: 10.4093/dmj.2016.40.1.79 26912157

30. Ko SH, Park YM, Yun JS, Cha SA, Choi EK, Han K, et al. Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: Nationwide population-based cohort study. J Diabetes Complications. 2018;32(2):157–163. doi: 10.1016/j.jdiacomp.2017.09.009 29196120

31. Choi YJ, Lee DH, Han KD, Yoon H, Shin CM, Park YS, et al. Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. PLoS One. 2018;13(9):e0201308. Epub 2018/09/20. doi: 10.1371/journal.pone.0201308 30231041

32. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract. 2007;75(1):72–80. Epub 2006/06/01. doi: 10.1016/j.diabres.2006.04.013 16735075

33. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J. 2011;35(6):561–6. Epub 2012/01/17. doi: 10.4093/dmj.2011.35.6.561 22247896

34. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. Epub 2009/05/06. doi: 10.7326/0003-4819-150-9-200905050-00006 19414839

35. Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25(3):562–7. Epub 2010/01/16. doi: 10.1111/j.1440-1746.2009.06117.x 20074156

36. Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27(1):91–5. Epub 2011/06/18. doi: 10.1111/j.1440-1746.2011.06816.x 21679251

37. Muhidin SO, Magan AA, Osman KA, Syed S, Ahmed MH. The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. J Obes. 2012;2012:637538. Epub 2013/01/11. doi: 10.1155/2012/637538 23304464

38. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60(6):829–36. Epub 2011/02/23. doi: 10.1136/gut.2011.237974 21339204

39. Huang KW, Leu HB, Wang YJ, Luo JC, Lin HC, Lee FY, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15(7):830–5. Epub 2013/02/13. doi: 10.1111/codi.12172 23398678

40. Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep. 2014;41(5):2989–97. Epub 2014/01/23. doi: 10.1007/s11033-014-3157-y 24449368

41. Min YW, Yun HS, Chang WI, Kim JY, Kim YH, Son HJ, et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol. 2012;36(1):78–83. Epub 2011/12/03. doi: 10.1016/j.clinre.2011.10.006 22133576

42. Sun LM, Lin MC, Lin CL, Liang JA, Jeng LB, Kao CH, et al. Nonalcoholic Cirrhosis Increased Risk of Digestive Tract Malignancies: A Population-Based Cohort Study. Medicine (Baltimore). 2015;94(49):e2080. Epub 2015/12/15. doi: 10.1097/md.0000000000002080 26656334

43. Uzel M, Sahiner Z, Filik L. Non-alcoholic fatty liver disease, metabolic syndrome and gastric cancer: Single center experience. J buon. 2015;20(2):662. Epub 2015/05/27. 26011365

44. Ha TH, Kim BG, Jeong D, Oh S, Kim W, Jung YJ, et al. Alcoholic Liver Disease Is Associated with an Increased Risk of Gastric Cancer. Dig Dis Sci. 2017;62(1):273–9. Epub 2016/10/28. doi: 10.1007/s10620-016-4352-6 27785709

45. Smith M, Zhou M, Whitlock G, Yang G, Offer A, Hui G, et al. Esophageal cancer and body mass index: results from a prospective study of 220,000 men in China and a meta-analysis of published studies. Int J Cancer. 2008;122(7):1604–10. doi: 10.1002/ijc.23198 18059032

46. Lahmann PH, Pandeya N, Webb PM, Green AC, Whiteman DC; Australian Cancer Study. Body mass index, long-term weight change, and esophageal squamous cell carcinoma: is the inverse association modified by smoking status? Cancer. 2012;118(7):1901–9. doi: 10.1002/cncr.26455 21960146

47. Pandur S, Pankiv S, Johannessen M, Moens U, Huseby NE. Gamma-glutamyltransferase is upregulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells. Free Radic Res. 2007;41(12):1376–84. Epub 2007/12/14. doi: 10.1080/10715760701739488 18075840

48. Huang H, Wang XP, Li XH, Chen H, Zheng X, Lin JH, et al. Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma. BMC Cancer. 2017;17(1):544. Epub 2017/08/16. doi: 10.1186/s12885-017-3523-y 28806937

49. Mok Y, Son DK, Yun YD, Jee SH, Samet JM. gamma-Glutamyltransferase and cancer risk: The Korean cancer prevention study. Int J Cancer. 2016;138(2):311–9. Epub 2015/06/27. doi: 10.1002/ijc.29659 26111622

50. Choi YJ, Lee DH, Han KD, Yoon H, Shin CM, Park YS, et al. Elevated serum gamma-glutamyltransferase is associated with an increased risk of oesophageal carcinoma in a cohort of 8,388,256 Korean subjects. PLoS One. 2017;12(5):e0177053. Epub 2017/05/06. doi: 10.1371/journal.pone.0177053 28475598

51. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016;17(5). Epub 2016/05/18. doi: 10.3390/ijms17050717 27187365

52. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(9):1154–61. Epub 2006/08/15. doi: 10.1016/j.cgh.2006.06.011 16904946

53. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009;10(4):412–9. Epub 2009/05/06. doi: 10.1111/j.1467-789X.2009.00594.x 19413701

54. Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer. 2011;104(1):51–9. Epub 2010/11/18. doi: 10.1038/sj.bjc.6606005 21081932

55. Cha JM, Kozarek RA, La Selva D, Gluck M, Ross A, Chiorean M, et al. Disparities in prevalence, location, and shape characteristics of colorectal neoplasia between South Korean and U.S. patients. Gastrointest Endosc. 2015;82(6):1080–6. Epub 2015/05/31. doi: 10.1016/j.gie.2015.04.018 26024585


Článek vyšel v časopise

PLOS One


2020 Číslo 1